复方天麻蜜环糖肽片联合倍他司汀治疗老年良性位置性眩晕的疗效观察

目的探讨复方天麻蜜环糖肽片联合甲磺酸倍他司汀片治疗老年良性位置性眩晕的临床疗效。方法选取2017年2月—2018年5月在南京医科大学附属南京医院(南京市第一医院)接受治疗的老年良性位置性眩晕患者134例为研究对象,随机将所有患者分为对照组(67例)和治疗组(67例)。对照组患者饭后口服甲磺酸倍他司汀片,6 mg/次,3次/d。治疗组在对照组治疗的基础上口服复方天麻蜜环糖肽片,1 g/次,3次/d。两组患者均连续治疗7 d。观察两组的临床疗效,同时比较两组患者的眩晕症状评分、药物起效时间、症状改善时间和不良反应发生情况。结果治疗后,对照组和治疗组的总有效率分别为82.09%、95.52%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者眩晕症状评分均明显降低,同组治疗前后比较差异具有统计学意义(P0.05);治疗后,治疗组眩晕症状评分显著低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,治疗组患者药物起效时间、症状改善时间均明显短于对照组,两组比较差异具有统计学意义(P0.05)。治疗期间,对照组不良反应发生率为13.43%,明显高于治疗组的4.48%,两组比较差异具有统计学意义(P0.05)。结论复方天麻蜜环糖肽片联合甲磺酸倍他司汀片治疗老年良性位置性眩晕具有较好的临床疗效,改善眩晕症状,不良反应发生率低,安全性好,具有一定的临床推广价值。

Clinical observation of Compound Armillaria Mellea Polysaccharide and Polypeptide Tablets combined with betahistine in treatment of benign positional vertigo in the elderly

Objective To explore the clinical efficacy of Compound Armillaria Mellea Polysaccharide and Polypeptide Tablets combined with Betahistine Mesilate Tablets in treatment of benign positional vertigo in the elderly. Methods Patients (134 cases) with benign positional vertigo in the elderly in Nanjing Hospital Affiliated to Nanjing Medical University (Nanjing First Hospital) from February 2017 to May 2018 were randomly divided into control (67 cases) and treatment (67 cases) group. Patients in the control group were po administered with Betahistine Mesilate Tablets, 6 mg/time, three times daily. Patients in the treatment group were po administered with Compound Armillaria Mellea Polysaccharide and Polypeptide Tablets on the basis of the control group, 1 g/time, three times daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacies were evaluated, and vertigo score, the times of drug onset and symptom improvement, and adverse reactions in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.09% and 95.52%, respectively, and there was difference between two groups (P<0.05). After treatment, vertigo scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the vertigo scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the times of drug onset and symptom improvement in the treatment group were significantly shorter than those in the control group (P<0.05). During the treatment, the incidence of adverse reactions in the control group was 13.43%, which was significantly higher than 4.48% in the treatment group, with significant difference between two groups (P<0.05). Conclusion Compound Armillaria Mellea Polysaccharide and Polypeptide Tablets combined with Betahistine Mesilate Tablets has clinical curative effect in treatment of benign positional vertigo in the elderly, can improve vertigo symptoms, with lower incidence of adverse reactions and good safety, which has a certain clinical application value.